News
Articles
Get tested for Mycoplasma genitalium—you might have it without even knowing it, and it could be a cause of infertility
Mycoplasma genitalium is a relatively common sexually transmitted infection about which little is known, as it often causes no symptoms. However, if left untreated, it can cause serious and long-term damage. And what’s worse, according to experts, is that it is becoming resistant to antibiotics. Mycoplasma genitalium affects both men and women, and although it is most commonly spread through unprotected vaginal or anal sex, transmission can also occur through contact between infected fingers and intimate areas.
Interview with the head of the GHC Genetics laboratory in Téma magazine
For years, colonoscopy has been one of the most effective methods for detecting colorectal cancer, but many patients fear the procedure and put off getting tested. Now, however, a new alternative is available: genetic testing using a blood sample. What does the future hold for this approach in conjunction with artificial intelligence? Renáta Michalovská, head of our molecular genetics and microbiology laboratory, discusses this in the latest issue of the weekly magazine Téma.
Listen to the podcast for the healthcare journal on predictive genetics
Viktor Furman, CEO of GHC Genetics, and Renáta Michalovská, head of the GHC Genetics laboratory, were guests on the Zdravotnický deník podcast, where they discussed with Tomáš Cikrt what predictive genetics actually offers today, its potential, and its clear limitations. In the podcast, they also addressed topics such as
We are introducing two new screening tests for colon and lung cancer.
GHC Genetics has introduced two new non-invasive screening tests, PulmoScreen and ColonScreen, which can detect serious diseases before they manifest themselves. These are blood screening tests for lung cancer and colorectal cancer. Both tests are based on the so-called analysis of DNA methylation in a blood sample and represent a modern, fast, and highly accessible form of prevention that can detect very early pathological changes in cells that later lead to the development of cancerous growths. By introducing these two screening tests, we are strengthening our position in the field of personalized and predictive medicine. We are putting into practice methods that were only available in research a few years ago. Thanks to them, we can help detect the disease at a stage when treatment is most effective, and patients have the best chance of a full recovery.
GHC Genetics to use innovative approach in sequencing oral and intestinal microbiome
Nanopore sequencing belongs to the so-called "third generation" of sequencing, which allows direct reading of single-stranded DNA or RNA without the need for prior amplification (e.g., using PCR) or chemical labeling. The use of nanopores for sequencing was first described in the late 1980s by several American scientists. David Deamer, George Church, and Hagan Bayley independently described the sequencing of a single DNA molecule using electrophoresis and membrane nanopores. This method does not use a fluorescent signal, but measures the voltage changes that occur when DNA passes through an electrically charged pore in the membrane.